2Hanahan D, Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J]. Cell, 1996, 86(3): 353-364.
3Yamanaka R, Zullo S A, Ramsey J, et al. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus [J]. Cancer Gene Ther, 2001, 8(10): 796—802.
4Chen C T, Lin J, Li Q, et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin [J]. Hu m Gene Ther, 2000, 11(4): 1983—1996.
5Sherif Z A, Nakai S, Pirollo K F, et al. Downmodulation of bFGF-binding protein expression following restoration of p53 function [J]. Cancer Gene Ther, 2001,8(10): 771—782.
6Pedram A, Razandi M, Levin E R. Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis [J]. Endocrinology, 2001, 142(4): 1578—586.
7Lu D, Jimenez X, Zhang H, et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor [J]. Cancer Res, 2001, 61 (19): 7002—7008.
8Im S A, Kim J S, Gomez-Manzano C, et al. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF [J]. Br J Cancer, 2001, 84(9): 1252—1257.
9Tortora G.Caputo R,Damiano V.et al. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis[J]. Clin Cancer Res,2001, 7(8):2537—2544.
10Guo Y L,Wang S.Colman R W. Kinino-statin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2001, 21 (9): 1427—1433.
同被引文献39
1Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymphatic vessel :expression in normal liver blood sinusoids and down regulation in human liver corner and cirrhosis. Cancer Res, 2001, 61: 8079-8084.
2Banerji S, Ni J, Wang SX, et al. LYVE-1 ,a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. Cell Biol, 1999, 144: 789-801.
3Prevo R, Banerji S, Ferguson DJ, et al. Mouse LYVE-1 is a endocytic receptor for hyaluronan in lymphatic endothelium. Biol Chem, 2001, 276: 19420-19430.
4Jackson DG, Prevo R, Clasper S. LYVE-1 ,the lymphatic system and tumor lymphangiogenesis. Trends Immunol, 2001, 22:317-321.
5Stacker SA, Caesar C, Baldwin M, et al. VEGF-D promotes the metastatic spread of tumor ceils via the lymphatics. Nature Medicine, 2001, 7: 186-191.
6Michaela S, Thom as H, David GJ, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Medicine, 2001, 7: 192-198.
7Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. European Molecular Biology Organization, 2001, 20:1223-1231.
8Zeidman L, Copeland BE, Warren S. Experimental studies on the spread of cancer in the lymphatic system. Absence of a lymphatic supply in carcinoma. Cancer,1955, 8: 123-127.
9Tanigawa N, Kanazawa T, Satomura K, et al. Experimental studies on lymphatic vascular changes in the development of cancer. Lymphology, 1981, 14:149-154.
10Duenne AA, Werner JA. Functional anatomy of lymphatic vessels under the aspect of tumor invasion.Cancer Research, 2000, 157: 82-89.
